ImmunityBio has around $130.1 million in cash, enough to fund operations for at least the next 12 months. Read why I’m very bullish on IBRX stock.
ImmunityBio: CAR-NK Cell Therapy Data For NHL Expected In Second Half Of 2025
view original post
ImmunityBio has around $130.1 million in cash, enough to fund operations for at least the next 12 months. Read why I’m very bullish on IBRX stock.